Evidence map›Paper›PMID 27775165›Full record

ArticleThe Prostate2017

Predicting Prostate Cancer Recurrence After Radical Prostatectomy.

Abra Jeffers, Vanessa Sochat, Michael W Kattan, Changhong Yu, Erin Melcon, Kosj Yamoah, Timothy R Rebbeck, Alice S Whittemore

Erratum issuedAbstract read
In one paragraph

Article in The Prostate, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Racial disparities in biochemical recurrence of prostate cancer.American journal of clinical and experimental urology · 2022
    Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

Abra JeffersPrecision Health Economics, Austin, Texas.
Vanessa SochatDepartment of Biomedical Data Sciences, Stanford University School of Medicine, Stanford, California.
Michael W KattanDepartment of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio.
Changhong YuDepartment of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio.
Erin MelconDepartment of Health Research and Policy, Stanford University School of Medicine, Stanford, California.
Kosj YamoahDepartment of Urology, University of Pennsylvania, Philadelphia, Pennsylvania.
Timothy R RebbeckDepartment of Epidemiology, Harvard University School of Public Health, Boston, Massachusetts.
Alice S WhittemoreDepartment of Health Research and Policy, Stanford University School of Medicine, Stanford, California.
Stanford University · USCleveland Clinic · USHarvard University · USTexas Department of State Health Services · USUniversity of Pennsylvania · US

Funding

Segregation and Racial Disparities in Prostate CancerP50CA105641 · NCI · UNIVERSITY OF PENNSYLVANIA · PI REBBECK, TIMOTHY R · 2003 to 2009
$9.6M
Statistical Methods for Genetic EpidemiologyR01CA094069 · NCI · STANFORD UNIVERSITY · PI WHITTEMORE, ALICE · 2002 to 2016
$7.7M
Research Traiing/Education CoreP60MD006900 · NIMHD · UNIVERSITY OF PENNSYLVANIA · PI REBBECK, TIMOTHY R · 2012 to 2016
$6.6M
NCI NIH HHS P50 CA105641NCI NIH HHS R01 CA094069NIMHD NIH HHS P60 MD006900
6 · The paper itself

Abstract

backgroundProstate cancer prognosis is variable, and management decisions involve balancing patients' risks of recurrence and recurrence-free death. Moreover, the roles of body mass index (BMI) and race in risk of recurrence are controversial [1,2]. To address these issues, we developed and cross-validated RAPS (Risks After Prostate Surgery), a personal prediction model for biochemical recurrence (BCR) within 10 years of radical prostatectomy (RP) that includes BMI and race as possible predictors, and recurrence-free death as a competing risk.

methodsRAPS uses a patient's risk factors at surgery to assign him a recurrence probability based on statistical learning methods applied to a cohort of 1,276 patients undergoing RP at the University of Pennsylvania. We compared the performance of RAPS to that of an existing model with respect to calibration (by comparing observed and predicted outcomes), and discrimination (using the area under the receiver operating characteristic curve (AUC)).

resultsRAPS' cross-validated BCR predictions provided better calibration than those of an existing model that underestimated patients' risks. Discrimination was similar for the two models, with BCR AUCs of 0.793, 95% confidence interval (0.766-0.820) for RAPS, and 0.780 (0.745-0.815) for the existing model. RAPS' most important BCR predictors were tumor grade, preoperative prostate-specific antigen (PSA) level and BMI; race was less important [3]. RAPS' predictions can be obtained online at https://predict.shinyapps.io/raps.

conclusionRAPS' cross-validated BCR predictions were better calibrated than those of an existing model, and BMI information contributed substantially to these predictions. RAPS predictions for recurrence-free death were limited by lack of co-morbidity data; however the model provides a simple framework for extension to include such data. Its use and extension should facilitate decision strategies for post-RP prostate cancer management. Prostate 77:291-298, 2017. © 2016 Wiley Periodicals, Inc.

Indexed as

AgedCohort StudiesHumansLongitudinal StudiesMaleMiddle AgedNeoplasm Recurrence, LocalPredictive Value of TestsProstatectomyProstate-Specific AntigenProstatic NeoplasmsROC CurveProstate-Specific Antigenbody mass indexcalibration discriminationprediction modelprostate cancer recurrence

Identifiers

PMID27775165
PMCPMC5877452
OpenAlexW2544178345

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.